Quantitative analysis of streptococcal exoprotein flow to the host receptor--exact basis for therapy of tumors and Alzheimer's disease.
Zahradník. F J FJ
Key Findings
- Streptococcal NAD+-nucleosidase binds to a host receptor until saturation
- Authors suggest disease may involve misdirected protein flow to unwanted sites
- They claim low‑molar‑mass drug therapy is conceptually wrong for these conditions
Practical Outcomes
- There are no actionable insights for using humanin or any biohacking strategies. The findings are theoretical and not relevant to longevity, metabolic health, or performance optimization.
Summary
The study examines how a bacterial protein binds to a heart tissue extract and argues that small‑molecule drugs may not work for diseases like cancer or Alzheimer’s. It does not mention humanin or give any practical advice for health‑optimizing protocols.
Abstract
The basis of a bacterial pathogenic process consists in the change of a certain host structure to a completely different one. This is accomplished by binding of a bacterial protein product to the host structure. Streptococcal NAD+-nucleosidase was explored as to its binding to the host receptor represented by beef heart extract. The bacterial product was found to bind to the host structure until the available host structure was fully saturated. The similarity of the above flows of macromolecules with some models of morphogenesis indicates the existence of diseases associated with the flow of a protein to the undesirable site in the organism. In such a case therapy with low-molar-mass substances is wrong in principle.
Study Information
pubmed
2005
10.1007/bf02931295